This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

3 Top Funds' Best Stock Picks Crush S&P 500

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

T. Rowe Price Health Sciences Fund (PRHSX), a $3 billion fund with a portfolio of 158 stocks, is up 19% this year and 43.5% over the past 12 months. The diverse fund has only 27% of its assets in its top 10 holdings and the annual portfolio turnover is a slim 36%. The fund favors small- and mid-cap stocks.

Kris Jenner has been the manager since 2000.

Alexion Pharmaceuticals (ALXN), the top holding at 6.4% of the fund, is up 15% this year. The company focuses on the development and marketing of drugs for life-threatening medical conditions. Mutual funds own 59% of its shares.

Valeant Pharmaceuticals International (VRX - Get Report), up 75% this year, makes up 3.6% of the fund. The Canadian company, composed of the former pharmaceutical firms Valeant Pharmaceuticals and Biovail International, licenses and develops specialty drugs in the neurology and dermatology category. It sells more than 100 branded products.

Gilead Sciences (GILD - Get Report), 3% of the portfolio, is up 12.9% this year. The company develops and markets therapies to treat life-threatening infectious diseases.






The $1.2 billion Fidelity Select Biotechnology Fund (FBIOX) has a return of 18.6% this year and 37% over the past 12 months. The 95-stock fund has been managed by Rajiv Kaul since October 2005. The annual portfolio turnover is relatively high, at 119%, and 57% of its assets are concentrated in the top 10 positions.

Its top holding is the biotechnology giant Amgen (AMGN - Get Report), which at 18.4% of the fund, is more than double the allocation of the next largest stock. Amgen has risen 9% this year. The company is a leader in biotechnology-based human therapeutics, with expertise in renal disease and cancer-care products.

Alexion Pharmaceutical (ALXN) is the second-largest holding, at 6.7% of fund's assets.

Vertex Pharmaceutical (VRTX - Get Report), 6.5% of the fund, is up 58.6% this year. It is a developer of small-molecule drugs for the treatment of life-threatening diseases. It is close to commercializing telaprevir, a hepatitis-C treatment in late-stage development with the potential to achieve blockbuster status, according to Morningstar analysts.

The fourth-largest position is Biomarin Pharmaceutical (BMRN - Get Report), at 4.5% of the fund. The company, which is building a portfolio of genetic disease therapeutics, many used in the treatment or rare diseases, is up 2% this year.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMGN $160.44 0.90%
BMRN $129.54 1.91%
GILD $112.46 2.45%
WLP $136.01 1.43%
WBMD $45.63 -0.07%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs